ArticleAndrology2026
Association Between Isolated Postprandial Dyslipidemia And Erectile Dysfunction.
Article in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostprandial lipid testing is increasingly recognized as a marker of vascular health. However, its relationship with erectile dysfunction (ED) remains largely unexplored. Isolated postprandial dyslipidemia (IPD), in particular, may evade detection using conventional fasting-based assessments, despite potential atherogenic effects.
objectivesTo evaluate the association between IPD and erectile function, comparing the prevalence and severity of ED among men with IPD, combined dyslipidemia (CD), and those without dyslipidemia (WD). MATERIALS AND
methodsIn this cross-sectional study, sexually active men aged ≥18 years underwent same-day fasting and postprandial lipid testing, as well as erectile function evaluation using the International Index of Erectile Function - Erectile Function domain (IIEF-EF) questionnaire. Dyslipidemia was defined according to the 2019 European Society of Cardiology/European Atherosclerosis Society criteria. Patients were categorized as WD (no dyslipidemia), IPD (postprandial abnormalities only), or CD (both fasting and postprandial abnormalities). Multivariable logistic regression was performed, adjusting for age, smoking status, BMI, and hypertension. The primary outcome was the prevalence of ED (IIEF-EF ≤25); secondary outcomes included ED severity and comparisons across lipid profile subgroups.
resultsAmong 351 men, ED prevalence was higher in the IPD (55.1%) and CD (57.0%) groups compared to WD (32.8%; p < 0.001). Median (IQR) IIEF-EF scores were 26 (25-28) in the WD group, 22 (20-23) in the IPD group, and 21 (19-23) in the CD group. The differences between WD and both IPD and CD exceeded the minimal clinically important difference (4 points) and were statistically significant (p < 0.001). Adjusted analyses confirmed increased odds of ED in IPD (odds ratio [OR] = 2.36; 95% confidence interval [CI]: 1.41-3.96) and CD (OR = 2.58; 95% CI: 1.43-4.65) versus WD. ED severity was also greater in the IPD and CD groups. No differences emerged between IPD and CD in any outcome. Among IPD subtypes, elevated postprandial triglycerides were most common, but no single lipid abnormality was independently associated with ED severity.
conclusionIPD is associated with both the prevalence and severity of ED, paralleling the impact of chronic dyslipidemia. Postprandial lipid testing may reveal hidden metabolic risks relevant to sexual health and should be considered in the evaluation of ED. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.